Erschienen in:
01.12.2014 | Commentary
A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients
verfasst von:
Masaki Ohya, Takashi Shigematsu
Erschienen in:
Clinical and Experimental Nephrology
|
Ausgabe 6/2014
Einloggen, um Zugang zu erhalten
Excerpt
In recent years, there have been an increasing number of reports about the association between hyperuricemia and other diseases such as hypertension, hyperlipidemia, arteriosclerosis, cardiovascular disease and chronic kidney disease [
1‐
3]. Allopurinol has long been regarded as a first-line drug for the treatment of hyperuricemia, but side effects such as renal dysfunction, hepatic dysfunction, Stevens-Johnson syndrome, and hypersensitivity vasculitis have been reported [
4‐
6]. New urate-lowing agent had been expected during long time like 30 years or more. …